Press Releases July 2, 2026 08:30 AM

Integra LifeSciences Appoints Topaz Kirlew Chief Regulatory Officer

Integra LifeSciences names Topaz Kirlew as Chief Regulatory Officer to strengthen global regulatory capabilities

By Sofia Navarro
Share
Twitter Reddit Facebook LinkedIn
IART

Integra LifeSciences has appointed Topaz Kirlew as its Chief Regulatory Officer. Kirlew, who has over 35 years of healthcare and medical technology regulatory experience, has been serving as the interim regulatory leader and will now lead the company’s global regulatory affairs organization, overseeing regulatory strategy, compliance, submissions, and transformation initiatives worldwide.

Integra LifeSciences Appoints Topaz Kirlew Chief Regulatory Officer
IART
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Topaz Kirlew’s appointment brings deep regulatory expertise to Integra LifeSciences, potentially enhancing compliance and submission strategies.
  • Kirlew has been instrumental in risk mitigation and building regulatory capabilities during her interim tenure since 2021.
  • Integra LifeSciences continues to focus on strengthening its regulatory functions as part of its broader mission to advance technologies in neurosurgery and tissue reconstruction.

PRINCETON, N.J., July 02, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a global leader in medical technology, today announced the appointment of Topaz Kirlew, DBA, MBA, as corporate vice president and chief regulatory officer. Kirlew will lead Integra's global regulatory affairs organization and oversee regulatory strategy, compliance, submissions, and transformation initiatives worldwide.

Kirlew served as the interim regulatory leader for the company over the past several months, leading the global regulatory organization during an important period for the company. In her interim capacity, she provided oversight of regulatory compliance, managed active submissions, and led risk mitigation efforts across the organization.

"Topaz brings deep regulatory experience, sound judgment, and a practical approach to helping the business move forward the right way," said Stuart Essig, chairman and chief executive officer of Integra LifeSciences. "She has earned the confidence of the leadership team, and I am pleased to have her in this role as we continue to strengthen our regulatory capabilities and advance our mission of restoring patients' lives."

Since joining Integra in 2021, Kirlew has played a key role in building the company's regulatory capabilities and advancing key business priorities. She brings more than 35 years of healthcare and medical technology industry experience spanning regulatory affairs, quality, operations, and clinical functions.

Prior to joining Integra, Kirlew held positions of increasing responsibility at several healthcare and medical technology organizations, including Danaher Corporation, Apyx Medical, Bio-Tissue, and the University of Miami's Diabetes Research Institute. She began her career as a clinical laboratory scientist, serving at leading healthcare institutions including the National Institutes of Health, Georgetown University Hospital, and the University of Maryland Medical Center.

Kirlew earned a bachelor’s degree in clinical laboratory science from Florida International University and holds a master's degree and a doctorate in business administration from Nova Southeastern University's School of Business and Entrepreneurship.

About Integra LifeSciences
Integra LifeSciences (Nasdaq: IART) is a global medical technology leader dedicated to restoring lives. We are advancing transformational care through impactful innovation in neurosurgery and tissue reconstruction, specialized fields that demand exceptional expertise and precision. Our portfolio of highly differentiated, gold-standard technologies is trusted by healthcare professionals to deliver transformative care. For the latest news and information about Integra and its products, please visit www.integralife.com.

Investor Relations:
Chris Ward
(609) 772-7736
[email protected]

Media Contact:
Laurene Isip
(609) 208-8121
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/1a23fae4-98d6-4910-9b3a-5172804e1e1c


Risks

  • The medical technology sector is heavily regulated; any missteps in regulatory compliance or delays in approvals could impact product launches and revenues.
  • Changes in healthcare laws and regulations globally could affect regulatory strategies and operational timelines.
  • Execution risk related to transformation initiatives and maintaining compliance amid evolving regulatory landscapes could affect operational efficiency.

More from Press Releases

Nordic American Tankers Ltd (NYSE: NAT) – Our ships are out of the Arabian Gulf Jul 2, 2026 First Merchants Corporation to Report Second Quarter 2026 Financial Results, Host Conference Call and Webcast Jul 2, 2026 Moomoo Launches "Moomoo Engine" — Unifying the Platform's Full Trading Toolkit Into One Connected System Jul 2, 2026 MacroGenics Completes Sale of GMP Manufacturing Operations to Bora Pharmaceuticals Jul 2, 2026 Virtuix to Present Recent Meta, Defense, and Financial Milestones at the Emerging Growth Conference Jul 2, 2026